FinscoFinsco

ADMA Biologics (US.ADMA)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ADMA · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion95.5%↓
ROE11.6%↑
Cash Conversion128.5%↑
D/E Ratio0.52↓
Gross Margin70.5%↑
US.ADMA (ADMA Biologics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    95.5%    ↓
ROE               11.6%    ↑
Cash Conversion  128.5%    ↑
D/E Ratio          0.52    ↓
Gross Margin      70.5%    ↑
Key Metrics
US.ADMA (ADMA Biologics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 95.5% ↓
ROE 11.6% ↑
Cash Conversion 128.5% ↑
D/E Ratio 0.52 ↓
Gross Margin 70.5% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies